Cyprotex Plc

Cyprotex Plc

August 17, 2005 02:31 ET

Cyprotex Enters Significant Long-Term Contract With Sepracor

LONDON, UNITED KINGDOM--(CCNMatthews - Aug. 17, 2005) - Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, is pleased to announce that it has entered into a significant long-term contract for Cyprotex's integrated Cloe offering with the major US-based pharmaceutical company, Sepracor Inc.

Commenting on the agreement, Robert Morrisson Atwater, Chief Executive Officer of Cyprotex PLC, said: "This is Cyprotex's first major US partnership which shows that our technologies, expertise and general approach are attracting a wider audience. This deal is clear demonstration that Cyprotex is gaining well deserved recognition as a valuable partner in drug discovery."

About Cyprotex

From its Cloe Screen® suite of assays, Cyprotex generates detailed profiles of a customer's compounds to include their absorption, distribution, metabolism, excretion and toxicity (ADME) properties. A partnership is structured with customers to provide essential early evaluation of compounds to support decision-making on the selection of lead series to take forward, in addition to providing follow-up experimental support for further investigating potential liabilities on smaller groups of compounds. This partnership will also ensure the steady supply of critical information for guiding a customer's lead optimisation and compound selection for clinical trials. Cyprotex provides a rapid turnaround of core compound property information on a weekly basis alongside its customer's chemistry design and lead optimisation efforts. Customers also use Cyprotex's Cloe PK® software to integrate and interpret the data - by predicting how these properties combine to affect the exposure level of compounds in the blood and major organs in the body over time.

For further information:

Cyprotex PLC

Robert Morrisson Atwater,
Chief Executive Officer Tel: +44 (0) 1625 505 100

Media enquiries:

Abchurch Communications

Heather Salmond / Samantha Robbins Tel: +44 (0) 20 7398 7700

Notes to editors

Cyprotex plc -

Cyprotex is a specialist provider of experimental and computational capabilities to support ADME/toxicity and pharmacokinetics assessment for drug discovery partners. Its core products include the Cloe Screen™ in vitro ADME/toxicity service, and Cloe PK™ - a pharmacokinetics prediction system which integrates core ADME and physicochemical compound data to predict compound levels in plasma and major organs in the body. This unique combination of technologies is aimed at improving pharmaceutical productivity by improving the quality of compound libraries and drug candidates progressing through the drug pipeline. Cyprotex is based in the UK and is listed on the London Stock Exchange (CRX).

Contact Information